Susquehanna International Group, LLP Sage Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

A detailed history of Susquehanna International Group, LLP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 227,528 shares of SAGE stock, worth $1.58 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

227,528

Previous 103,120 120.64%

Holding current value

$1.58 Million

Previous $1.93 Million 27.85%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$10.58 - $17.9 $1.32 Million - $2.23 Million	124,408 Added 120.64%	227,528 $2.47 Million
Q1 2024 May 07, 2024	SELL	$18.62 - $26.95 $2.88 Million - $4.16 Million	-154,527 Reduced 59.98%	103,120 $1.93 Million
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $3.43 Million - $4.46 Million	200,565 Added 351.36%	257,647 $5.58 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $444,159 - $1.3 Million	26,517 Added 86.76%	57,082 $1.17 Million
Q2 2023 Aug 11, 2023	SELL	$40.65 - $59.54 $4.48 Million - $6.57 Million	-110,284 Reduced 78.3%	30,565 $1.44 Million
Q1 2023 May 16, 2023	BUY	$37.27 - $46.57 $3 Million - $3.75 Million	80,504 Added 133.41%	140,849 $5.91 Million
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $184,892 - $250,408	-5,742 Reduced 8.69%	60,345 $2.3 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $8,102 - $10,860	-251 Reduced 0.38%	66,087 $2.59 Million
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $2.66 Million - $3.67 Million	-96,561 Reduced 59.28%	66,338 $2.14 Million
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $1.14 Million - $1.7 Million	37,097 Added 29.49%	162,899 $5.39 Million
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $710,440 - $903,098	-19,170 Reduced 13.22%	125,802 $5.35 Million
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $4.6 Million - $6.55 Million	114,178 Added 370.78%	144,972 $6.42 Million
Q2 2021 Aug 11, 2021	BUY	$54.88 - $79.29 $72,716 - $105,059	1,325 Added 4.5%	30,794 $1.75 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $4.34 Million - $5.94 Million	-61,391 Reduced 67.57%	29,469 $2.21 Million
Q4 2020 Feb 16, 2021	BUY	$58.41 - $89.06 $1.27 Million - $1.93 Million	21,686 Added 31.35%	90,860 $7.86 Million
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $4.33 Million - $6.58 Million	-105,339 Reduced 60.36%	69,174 $4.23 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $289,965 - $482,158	11,174 Added 6.84%	174,513 $7.26 Million
Q1 2020 May 15, 2020	BUY	$26.15 - $77.24 $3.2 Million - $9.45 Million	122,406 Added 299.04%	163,339 $4.69 Million
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $808,638 - $2.08 Million	13,437 Added 48.87%	40,933 $2.96 Million
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $1.86 Million - $2.52 Million	13,260 Added 93.14%	27,496 $3.86 Million
Q2 2019 Aug 16, 2019	BUY	$157.85 - $183.09 $1.05 Million - $1.22 Million	6,661 Added 87.93%	14,236 $2.61 Million
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $4.42 Million - $5.13 Million	-28,026 Reduced 78.72%	7,575 $1.39 Million
Q4 2018 Feb 14, 2019	SELL	$81.94 - $139.71 $8.91 Million - $15.2 Million	-108,751 Reduced 75.34%	35,601 $3.41 Million
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $5.54 Million - $6.78 Million	-40,129 Reduced 21.75%	144,352 $20.4 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $25.6 Million - $32.1 Million	182,538 Added 9394.65%	184,481 $28.9 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $40 Million - $50.6 Million	-262,925 Reduced 99.27%	1,943 $313,000
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $16.1 Million - $44.3 Million	264,868	264,868 $43.6 Million

Others Institutions Holding SAGE

# of Institutions

217

Shares Held

48.2M

Call Options Held

854K

Put Options Held

195K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $414M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Sage Therapeutics, Inc. Transaction History